PubMed Health treatment related to Hemochromatosis, Type 1: 63
Treatments for hemochromatosis include therapeutic phlebotomy (fleh-BOT-o-me), iron chelation (ke-LAY-shun) therapy , dietary changes, and treatment for complications. The goals of treating hemochromatosis include: Reducing the amount of iron in your body to normal levels Preventing or delaying organ damage from iron overload Treating complications of the disease Maintaining a normal amount of iron in your body for the rest of your life
Drugs for Hemochromatosis, Type 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 44)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Iron |
Approved |
Phase 4 |
|
7439-89-6 |
29936 |
Synonyms:
Carbonyl iron
Eisen
Electrolytic iron
Fe
FE (III) ion
Fe(3+)
Fe(III)
fer
Ferric ion
Ferric iron
Ferrum
|
Ferrum metallicum
Hierro
Iron powder
Iron(3+)
Iron, carbonyl
Iron, electrolytic
Iron, elemental
Iron, ion (fe(3+))
Iron, reduced
Reduced iron
|
|
2 |
|
Deferiprone |
Approved |
Phase 4 |
|
30652-11-0 |
2972 |
Synonyms:
1,2 Dimethyl 3 hydroxy 4 pyridinone
1,2 Dimethyl 3 hydroxypyrid 4 one
1,2 Dimethyl 3 hydroxypyridin 4 one
1,2-Dimethyl-3-hydroxy-4-pyridinone
1,2-Dimethyl-3-hydroxypyrid-4-one
1,2-Dimethyl-3-hydroxypyridin-4-one
3 Hydroxy 1,2 dimethyl 4 pyridinone
3-Hydroxy-1,2-dimethyl-4(1H)-pyridone
3-Hydroxy-1,2-dimethyl-4-pyridinone
APO-066
APO-66
CP20
CP-20
DEFERIPRON
DEFERIPRONA
DEFERIPRONE
DÉFÉRIPRONE
|
DEFERIPRONI
DEFERIPRONUM
DEFERYPRON
DIMETHYLHYDROXYPYRIDONE
DMOHPO
DN-18001AF
DN-180-01-AF
Ferriprox
HDMPP
HDMPP CPD
HDPP
L1
L-1
L1 Oral chelate
PL1
PL-1
|
|
3 |
|
Deferasirox |
Approved, Investigational |
Phase 4 |
|
201530-41-8 |
214348 5493381 |
Synonyms:
4-(3,5-Bis-(2-hydroxyphenyl)-(1,2,4)-triazol-1-yl)benzoic acid
DEFERASIROX
Deferasiroxum
Deferasiroxum [inn-latin]
Exjade
ICL 670
ICL 670a
|
ICL670
ICL-670
ICL670a
ICL-670a
Jadenu
JADENU SPRINKLE
|
|
4 |
|
Deferoxamine |
Approved, Investigational |
Phase 4 |
|
70-51-9 |
2973 |
Synonyms:
b, Deferoxamine
b, Desferrioxamine
Deferoxamide b
Deferoxamin
Deferoxamina
Deferoxamine
Déferoxamine
Deferoxamine b
Deferoxamine mesilate
Deferoxamine mesylate
Deferoxamine methanesulfonate
Deferoxaminum
Deferoximine
Deferrioxamine
Deferrioxamine b
Desferal
|
Desferioximine
Desferrioxamine
Desferrioxamine b
Desferrioxamine b mesylate
Desferroxamine
DF b
DFO
DFOA
DFOM
Mesilate, deferoxamine
Mesylate, deferoxamine
Mesylate, desferrioxamine b
Methanesulfonate, deferoxamine
N-Benzoylferrioxamine b
NSC-527604
|
|
5 |
|
Iron Chelating Agents |
|
Phase 4 |
|
|
|
6 |
|
Chelating Agents |
|
Phase 4 |
|
|
|
7 |
|
Hydroxyurea |
Approved |
Phase 3 |
|
127-07-1 |
3657 |
Synonyms:
Biosupressin
Carbamohydroxamate
Carbamohydroxamic acid
Carbamohydroximate
Carbamohydroximic acid
Carbamohydroxyamic acid
Carbamoyl oxime
Carbamyl hydroxamate
Carbamyl hydroxamic acid
Droxia
Droxia®|Hydrea®|hydroxycarbamide|Siklos®|SQ-1089|Xromi®
Hidrix
Hidroxicarbamida
HU
Hydrea
Hydreia
Hydroxicarbamidum
Hydroxycarbamid
Hydroxycarbamide
Hydroxycarbamidum
|
Hydroxycarbamine
Hydroxyharnstoff
Hydroxylurea
HYDROXYUREA
Hydura
Hydurea
Idrossicarbamide
Idrossicarbamide [Dcit]
Litaler
Litalir
N-Carbamoylhydroxylamine
N-HYDROXYUREA
NSC-32065
Oncocarbide
Onco-Carbide
Oxyurea
SIKLOS
SQ-1089
Sterile Urea
Ureaphil
|
|
8 |
|
Liver Extracts |
|
Phase 3 |
|
|
|
9 |
|
Anti-Infective Agents |
|
Phase 2 |
|
|
|
10 |
|
Hepcidins |
|
Phase 2 |
|
|
|
11 |
|
Chrysarobin |
|
Phase 2 |
|
|
|
12 |
|
Antirheumatic Agents |
|
Phase 2 |
|
|
|
13 |
|
Interleukin 1 Receptor Antagonist Protein |
|
Phase 2 |
|
|
|
14 |
|
Pharmaceutical Solutions |
|
Phase 2 |
|
|
|
15 |
|
Nifedipine |
Approved |
Phase 1 |
|
21829-25-4 |
4485 |
Synonyms:
4-(2'-Nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsaeuredimethylester
4-(2'-Nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsäuredimethylester
Adalat
Adalat 10
Adalat 20
Adalat 5
ADALAT A.R.
ADALAT CC
Adalat CR
Adalat Crono
Adalat Ft
Adalat Gits
Adalat Gits 30
ADALAT IC
Adalat LA
ADALAT LA 20
ADALAT LA 30
ADALAT LA 60
Adalat LP
Adalat Oros
Adalat PA
ADALAT RET
Adalat Retard
Adalat®|BAY-A-1040|Procardia®
Adalate
ADALATE LP
ADANIF XL
Adapine
Adapress
Adcock ingram brand OF nifedipine
ADIPINE
ADIPINE MR 10
ADIPINE MR 20
ADIPINE XL
Afeditab CR
Alat
Aldipin
Alfadal
Alonix
Alonix S
Alpha-Nifedipine Retard
ANGIOPINE 10
ANGIOPINE 40 LA
ANGIOPINE 5
ANGIOPINE MR 10
ANGIOPINE MR 20
Angipec
Anifed
Anpine
Apo-Nifed
Aprical
AWD pharma brand OF nifedipine
BAY a 1040
BAY-a-1040
Bayer brand OF nifedipine
Bonacid
CALANIF
CALCHAN MR 10
CALCHAN MR 20
Calcibloc
Calcigard
CALCILAT
Camont
Cardifen
Cardilat
CARDILATE MR
Cardionorm
Chronadalate
Chronadalate Lp
Citilat
Coracten
CORACTEN SR
CORACTEN XL
Coral
Cordafen
Cordaflex
Cordalat
Cordicant
Cordilan
Cordipin
Cordipine
Corinfar
CORODAY MR
Corotrend
Corynphar
Depin
Dignokonstant
Dilafed
Dilcor
Dipinkor
Duranifin
Ecodipi
Ecodipin
Ecodipin E
|
Fedcor
Fedcor Retard
Fenamon
Fenamon Sr
Fenigidin
Fenihidin
Fenihidine
FORTIPINE LA40
GENALAT 10 RET
GENALAT 20 RET
Glopir
Hadipin
Hexadilat
HYPOLAR RET 10
HYPOLAR RET 20
HYPOLAR XL 30
Introcar
KENTIPINE
KENTIPINE MR 10
KENTIPINE MR 20
Kordafen
Korinfar
KRKA brand OF nifedipine
Macorel
Megalat
Monohydrochloride, nifedipine
Myogard
N1fedilat
Nedipin
NEOZIPINE XL
Nicardia
Nifangin
Nifar
Nifdemin
Nifebene
Nifecard
Nifecor
Nifedepat
Nifedicor
Nifedin
Nifedine
NIFEDIPINE
Nifedipine bayer brand
Nifedipine gtis
Nifedipine krka brand
Nifedipine monohydrochloride
Nifedipine orion brand
Nifedipine pfizer brand
Nifedipine Retard
Nifedipine-gtis
Nifedipino
Nifedipinum
Nifedipres
NIFEDIPRESS MR 10
NIFEDIPRESS MR 20
Nifedirex LP
NIFEDOTARD 20 MR
Nifelan
Nifelat
Nifelat Q
Nifelate
NIFELEASE
NIFENSAR XL
NIFE-WOLFF
Nificard
Nifidine
Nifipen
NIFOPRESS MR
NIFOPRESS RET
NIMODREL MR 10
NIMODREL MR 20
NIMODREL XL
Niphedipine
NIVATEN RET
Orion brand OF nifedipine
Orix
Oxcord
Pfizer brand OF nifedipine
Pidilat
Procardia
Procardia XL
Sepamit
SLOFEDIPINE XL 30
SLOFEDIPINE XL 60
TENSIPINE MR 10
TENSIPINE MR 20
Tibricol
UNIPINE XL
VALNI 20 RET
VALNI XL
VASAD
Vascard
Zenusin
|
|
16 |
|
Calcium polycarbophil |
Approved |
Phase 1 |
|
126040-58-2 |
|
Synonyms:
Calcium polycarbophil
Polycarbophil calcium
|
|
|
17 |
|
Hormones |
|
Phase 1 |
|
|
|
18 |
|
Vasodilator Agents |
|
Phase 1 |
|
|
|
19 |
|
Calcium, Dietary |
|
Phase 1 |
|
|
|
20 |
|
calcium channel blockers |
|
Phase 1 |
|
|
|
21 |
|
Tocolytic Agents |
|
Phase 1 |
|
|
|
22 |
|
Gastrointestinal Agents |
|
Phase 1 |
|
|
|
23 |
|
Cathartics |
|
Phase 1 |
|
|
|
24 |
|
Laxatives |
|
Phase 1 |
|
|
|
25 |
|
Psyllium |
|
Phase 1 |
|
|
|
26 |
|
Calcium |
Nutraceutical |
Phase 1 |
|
7440-70-2 |
271 |
Synonyms:
Ca
Ca(2+)
Ca2+
Calcio
CALCIUM
Calcium element
|
CALCIUM ion
Calcium(2+)
Calcium, doubly charged positive ion
Calcium, elemental
Elemental calcium
Kalzium
|
|
27 |
|
Pantoprazole |
Approved |
|
|
102625-70-7, 138786-67-1 |
4679 |
Synonyms:
6-(DIFLUOROMETHOXY)-2-{[(3,4-DIMETHOXYPYRIDIN-2-YL)METHANE]SULFINYL}-1H-1,3-BENZODIAZOLE
Astropan
BY-1023
PAN023
Pantoloc
PANTOLOC CONTROL
Pantopan
Pantoprazol
Pantoprazol [INN-Spanish]
PANTOPRAZOLE
Pantoprazole Na
Pantoprazole sodium
Pantoprazole sodium hydrate
Pantoprazolum
Pantoprazolum [INN-Latin]
|
Pantoprozole
Pantor
Pantozol
PROTIUM
PROTIUM I.V.
Protonix
Protonix i.v.
Protonix IV
SK And F 96022
SK And F96022
SK And F-96022
SK&F-96022
SK-96022
SKF-96022
|
|
28 |
|
Tacrolimus |
Approved, Investigational |
|
|
104987-11-3 |
6473866 445643 |
Synonyms:
(-)-FK 506
Anhydrous tacrolimus
Anhydrous, tacrolimus
Cilag brand OF tacrolimus
FK5
FK506
FK-506
FK506|fujimycin|Prograf®|Protopic®
FR-900506
FUJIMYCIN
Fujisawa brand OF tacrolimus
Janssen brand OF tacrolimus
|
K506
LCP-Tacro
Prograf
Prograft
PROTOPIC
Tacarolimus
TACROLIMUS
Tacrolimus anhydrous
tacrolimus hydrate
TACROLIMUS MONOHYDRATE
Tacrolimus, anhydrous
|
|
29 |
|
Ethanol |
Approved |
|
|
64-17-5 |
702 |
Synonyms:
[CH2Me(OH)]
[OEtH]
1-Hydroxyethane
ABLYSINOL
Absolute alcohol
Absolute ethanol
Absolute ethyl alcohol
Aethanol
Aethylalkohol
Alcare hand degermer
Alcohol
Alcohol (ethyl)
Alcohol anhydrous
Alcohol denatured
ALCOHOL DETERMINATION--ALCOHOL
Alcohol etilico
Alcohol etílico
Alcohol, absolute
Alcohol, Dehydrated
Alcohol, denatured
ALCOHOL, DILUTED
Alcohol, ethyl
Alcohol, grain
ALCOHOL, RUBBING
Alcohols
Alcool ethylique
Alcool éthylique
Alcool etilico
Algrain
Alkohol
Alkoholu etylowego
Aminoethanol
Anhydrol
Anhydrous alcohol
Anhydrous ethanol
Äthanol
Äthylalkohol
B3324
Beta-Aminoethanol
Beta-Aminoethyl Alcohol
Beta-Ethanolamine
Beta-Hydroxyethylamine
C2H5OH
Caswell No. 426
Colamine
Cologne spirit
Cologne spirits
Dehydrated alcohol
Dehydrated ethanol
Denatured alcohol
Denatured Alcohol Cd-10
Denatured Alcohol Cd-5
Denatured Alcohol Cd-5a
Denatured Alcohol Sd-1
Denatured Alcohol Sd-13a
Denatured Alcohol Sd-17
Denatured Alcohol Sd-23a
Denatured Alcohol Sd-28
Denatured Alcohol Sd-30
Denatured Alcohol Sd-39b
Denatured Alcohol Sd-39c
Denatured Alcohol Sd-3a
Denatured Alcohol Sd-40m
Denatured ethanol
Desinfektol el
Diluted alcohol
Distilled spirits
DRINKING ALCOHOL
E1510
Envision Conditioner Pdd 9020
ETA
Etanol
|
Etanolo
ETHANOL
éthanol
Ethanol 200 proof
Ethanol Absolute
Ethanol Absolute Bp
Ethanol Anhydrous
Ethanol Extra Pure
Ethanol solution
Ethanol, Silent Spirit
Ethicap
Ethyl alc
Ethyl alcohol
Ethyl Alcohol & Water, 10%
Ethyl Alcohol & Water, 20%
Ethyl Alcohol & Water, 30%
Ethyl Alcohol & Water, 40%
Ethyl Alcohol & Water, 5%
Ethyl Alcohol & Water, 50%
Ethyl Alcohol & Water, 60%
Ethyl Alcohol & Water, 70%
Ethyl Alcohol & Water, 80%
Ethyl Alcohol & Water, 95%
Ethyl Alcohol & Water, 96%
Ethyl alcohol anhydrous
Ethyl alcohol in alcoholic beverages
Ethyl alcohol usp
Ethyl Alcohol, Anhydrous
Ethyl Alcohol, Denatured
Ethyl hydrate
Ethyl hydroxide
Ethylol
Ethylolamine
EtOH
FEMA NO. 2419
Fermentation alcohol
Glycinol
Grain alcohol
Hinetoless
HSDB 531
Hydroxyethane
Infinity pure
Jaysol
Jaysol S
Lux
METHYLATED MINERAL
Methylated Spirit Mineralised
Methylcarbinol
Molasses alcohol
NCI-C03134
NSC-85228
PM-6193-200
Potato alcohol
Punctilious ethyl alcohol
Pyro
Reagent Alcohol
Silent spirit
SPIRIGEL
Spirit
Spirits OF wine
Spiritus vini
Spirt
SURG
Synasol
Tecsol
Tecsol C
Thanol
Thiofaco M-50
Undenatured ethanol
USAF EK-1597
VODKA
|
|
30 |
|
Pancrelipase |
Approved, Investigational |
|
|
53608-75-6 |
8519 |
Synonyms:
1,4-ALPHA-D- GLUCAN GLUCANOHYDROLASE
ACCELERASE
COTAZYM
COTAZYM-S
CREON
Endothall
Endothall dipotassium salt
Endothall disodium salt
Endothall disodium salt, (endo,endo)-isomer
Endothall, diammonium salt
ENTOLASE
ILOZYME
KU-ZYME HP
LIPANCREATIN
lipase
|
PA
Pancrealipase
PANCREASE
PANCREATIC ALPHA-AMYLASE PRECURSOR
Pancreatic extract pancrelipase
Pancreatic protease
Pancreatin
Pancreatinum
PANCRELIPASE
Pancrelipase (amylase
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)
protease)
VIOKASE
ZYMASE
|
|
31 |
|
Kava |
Approved, Investigational, Nutraceutical |
|
|
9000-38-8 |
|
32 |
|
Aspartic acid |
Approved, Nutraceutical |
|
|
56-84-8 |
5960 |
Synonyms:
(+)-Aspartate
(+)-Aspartic acid
(+-)-Aspartic acid
(2S)-2-AMINOBUTANEDIOIC ACID
(2S)-2-AMINOSUCCINIC ACID
(2S)-Aspartate
(2S)-Aspartic acid
(L)-Aspartate
(L)-Aspartic acid
(R)-2-Aminosuccinate
(R,S)-Aspartic acid
(S)-(+)-Aspartate
(S)-(+)-Aspartic acid
(S)-2-Aminobutanedioate
(S)-2-Aminobutanedioic acid
(S)-2-Aminosuccinate
(S)-2-Aminosuccinic acid
(S)-Aminobutanedioate
(S)-Amino-butanedioate
(S)-Aminobutanedioic acid
(S)-Amino-butanedioic acid
(S)-Aspartate
(S)-Aspartic acid
[<sup>3</sup>H]-L-aspartate|[<sup>3</sup>H]-L-aspartic acid
2-Amino-3-methylsuccinate
2-Amino-3-methylsuccinic acid
2-Aminosuccinate
2-Aminosuccinic acid
ácido aspártico
Acidum asparticum
alpha-Aminosuccinate
alpha-Aminosuccinic acid
Aminosuccinate
Ammonium aspartate
Asp
Asparagate
Asparagic acid
Asparaginate
Asparaginic acid
Asparatate
ASPARTate
Aspartate magnesium hydrochloride
Aspartate, ammonium
Aspartate, calcium
Aspartate, dipotassium
Aspartate, disodium
Aspartate, magnesium
Aspartate, monopotassium
Aspartate, monosodium
Aspartate, potassium
Aspartate, sodium
|
ASPARTIC ACID
Aspartic acid, ammonium salt
Aspartic acid, calcium salt
Aspartic acid, dipotassium salt
Aspartic acid, disodium salt
Aspartic acid, hydrobromide
Aspartic acid, hydrochloride
Aspartic acid, magnesium (1:1) salt, hydrochloride, trihydrate
Aspartic acid, magnesium (2:1) salt
Aspartic acid, magnesium-potassium (2:1:2) salt
Aspartic acid, monopotassium salt
Aspartic acid, monosodium salt
Aspartic acid, potassium salt
Aspartic acid, sodium salt
Calcium aspartate
D
Dipotassium aspartate
Disodium aspartate
FEMA NO. 3656
H-Asp-OH
Hydrobromide aspartic acid
Hydrochloride aspartic acid
Hydrochloride, aspartate magnesium
L Aspartate
L Aspartic acid
L-(+)-Aspartate
L-(+)-Aspartic acid
L-Aminosuccinate
L-Aminosuccinic acid
L-Asp
L-Asp|L-aspartate
L-Asparagate
L-Asparagic acid
L-Asparaginate
L-Asparaginic acid
L-Asparaginsaeure
L-Asparaginsäure
L-Aspartate
L-Aspartic acid
Magnesiocard
Magnesium aspartate
MG 5 Longoral
MG5Longoral
MG-5-Longoral
Monopotassium aspartate
Monosodium aspartate
NSC-3973
Poly-DL-succinimide
Polysuccinimide
Potassium aspartate
Sodium aspartate
|
|
33 |
|
Trichostatin A |
Experimental |
|
|
58880-19-6 |
5562 444732 |
Synonyms:
A-300-I
ANTIBIOTIC A-300
GNF-PF-1011
N-Hydroxy7-[4-(dimethylamino)phenyl]-4,6-dimethyl-7-oxohepta-2,4-dienimidate
|
TRICHOSTATIN
TRICHOSTATIN(S)
TSA
|
|
34 |
|
Anti-Ulcer Agents |
|
|
|
|
|
35 |
|
Antacids |
|
|
|
|
|
36 |
|
Proton Pump Inhibitors |
|
|
|
|
|
37 |
|
Iron Supplement |
|
|
|
|
|
38 |
|
Calcineurin Inhibitors |
|
|
|
|
|
39 |
|
Immunosuppressive Agents |
|
|
|
|
|
40 |
|
Immunologic Factors |
|
|
|
|
|
41 |
|
bilirubin |
|
|
|
635-65-4 |
5280352 |
Synonyms:
(4Z,15Z)-Bilirubin ixa
(Z,Z)-Bilirubin ixa
1,10,19,22,23,24-Hexahydro-2,7,13,17-tetramethyl-1,19-dioxo-3,18-divinylbiline-8,12-dipropionate
1,10,19,22,23,24-Hexahydro-2,7,13,17-tetramethyl-1,19-dioxo-3,18-divinyl-biline-8,12-dipropionate
1,10,19,22,23,24-Hexahydro-2,7,13,17-tetramethyl-1,19-dioxo-3,18-divinylbiline-8,12-dipropionic acid
1,10,19,22,23,24-Hexahydro-2,7,13,17-tetramethyl-1,19-dioxo-3,18-divinyl-biline-8,12-dipropionic acid
2,17-Diethenyl-1,10,19,22,23,24-hexahydro-3,7,13,18-tetramethyl-1,19-dioxo-21H-biline-8,12-dipropanoate
2,17-Diethenyl-1,10,19,22,23,24-hexahydro-3,7,13,18-tetramethyl-1,19-dioxo-21H-biline-8,12-dipropanoic acid
2,7,13,17-Tetramethyl-1,19-dioxo-3,18-divinyl-1,10,19,22,23,24-hexahydro-21H-biline-8,12-dipropanoate
2,7,13,17-Tetramethyl-1,19-dioxo-3,18-divinyl-1,10,19,22,23,24-hexahydro-21H-biline-8,12-dipropanoic acid
3-(2-((3-(2-Carboxyethyl)-4-methyl-5-((3-methyl-5-oxo-4-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl)-1H-pyrrol-2-yl)methyl)-4-methyl-5-((4-methyl-5-oxo-3-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl)-1H-pyrrol-3-yl)propanoate
3-(2-((3-(2-Carboxyethyl)-4-methyl-5-((3-methyl-5-oxo-4-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl)-1H-pyrrol-2-yl)methyl)-4-methyl-5-((4-methyl-5-oxo-3-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl)-1H-pyrrol-3-yl)propanoic acid
3-(2-((3-(2-Carboxyethyl)-4-methyl-5-[(Z)-(3-methyl-5-oxo-4-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl]-1H-pyrrol-2-yl)methyl)-4-methyl-5-[(Z)-(4-methyl-5-oxo-3-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene
3-[2-[[3-(2-Carboxyethyl)-5-[(3-ethenyl-4-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(4-ethenyl-3-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoate
|
3-[2-[[3-(2-Carboxyethyl)-5-[(3-ethenyl-4-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(4-ethenyl-3-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoic acid
3-[2-[[3-(2-Carboxyethyl)-5-[(Z)-(3-ethenyl-4-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(Z)-(4-ethenyl-3-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoate
3-[2-[[3-(2-Carboxyethyl)-5-[(Z)-(3-ethenyl-4-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(Z)-(4-ethenyl-3-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoic acid
8,12-Bis(2-carboxyethyl)-2,7,13,17-tetramethyl-3,18-divinylbiladiene-ac-1,19(21H,24H)-dione
BILIRUBIN
Bilirubin IX alpha
Bilirubin ixalpha
Bilirubin IX-alpha
Bilirubin(Z,Z)
Bilirubin-ixalpha
Cholerythrin
Hematoidin
NSC-26685
|
|
42 |
|
N-Methylaspartate |
|
|
|
|
|
43 |
|
Pancreatin |
|
|
|
|
|
44 |
|
D-Alanine |
Experimental, Nutraceutical |
|
|
302-72-7, 338-69-2, 56-41-7 |
101757026 602 71080 5950 |
Synonyms:
(2R)-2-Aminopropanoate
(2R)-2-Aminopropanoic acid
(2R)-2-Aminopropionic acid
(2S)-2-Aminopropanoate
(2S)-2-AMINOPROPANOIC ACID
(a-D-Mannosyl)7-b-D-mannosyl-diacetylchitobiosyl-L-asparagine, isoform a (protein)
(R)-2-Aminopropanoate
(R)-2-Aminopropanoic acid
(R)-2-Aminopropionic acid
(R)-Alanine
(S)-(+)-Alanine
(S)-2-Aminopropanoate
(S)-2-Amino-propanoate
(S)-2-Amino-propanoic acid
(S)-2-AMINOPROPANOIC ACID
(S)-ALANINE
(Α-D-mannosyl)7-β-D-mannosyl-diacetylchitobiosyl-L-asparagine, isoform a (protein)
[<sup>14</sup>C]-alanine
[<sup>3</sup>H]-alanine
2-Aminopropanoate
2-Aminopropanoic acid
2-Aminopropionate
2-Aminopropionic acid
2-Ammoniopropanoate
2-Ammoniopropanoic acid
A
a-Alanine
a-Aminopropionate
a-Aminopropionic acid
Abufène
ALA
Alanin
Alanina
Alanine
Alanine doms-adrian brand
Alanine, L isomer
Alanine, L-isomer
Alaninum
alpha-Alanine
alpha-Aminopropanoate
alpha-Aminopropanoic acid
alpha-Aminopropionate
|
alpha-Aminopropionic acid
D(-)-a -Alanine
D-(-)-Alanine
D(-)-alpha-Alanine
D(-)-Α-alanine
D-2-Aminopropionate
D-2-Aminopropionic acid
D-a-Alanine
D-a-Aminopropionate
D-a-Aminopropionic acid
DAL
D-Ala
D-Alanin
D-ALANINE
D-alpha-Alanine
D-alpha-Aminopropionate
D-alpha-Aminopropionic acid
Doms adrian brand OF alanine
Doms-adrian brand OF alanine
D-Α-alanine
D-Α-aminopropionate
D-Α-aminopropionic acid
E639
Ellagate arabinoside
L Alanine
L-(+)-Alanine
L-2-Aminopropanoate
L-2-Aminopropanoic acid
L-2-Aminopropionate
L-2-AMINOPROPIONIC ACID
L-a-Alanine
L-a-Aminopropionate
L-a-Aminopropionic acid
L-ALA
L-Alanin
L-Alanine
L-ALPHA-ALANINE
L-alpha-Aminopropionate
L-alpha-Aminopropionic acid
L-Isomer alanine
L-Α-ALANINE
NSC-206315
|
|
Interventional clinical trials:
(show top 50)
(show all 62)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Pilot Pharmacokinetic Study In Patients With Inadequate Response To Deferasirox (Exjade) |
Completed |
NCT00749515 |
Phase 4 |
Deferoxamine;Deferasirox |
2 |
A Single-arm, Open-label Study of the Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food |
Completed |
NCT00845871 |
Phase 4 |
deferasirox: |
3 |
Randomized Trial Comparing the Relative Efficacy of Deferiprone to That of Deferoxamine in Removing Excess Cardiac Iron in Thalassemia Major Patients |
Completed |
NCT00105495 |
Phase 4 |
Ferriprox (deferiprone);Desferal (deferoxamine) |
4 |
1-year Extension to CICL670A2402 an Open-label, Multi-center Trial of the Efficacy and Safety of Long-term Treatment With Deferasirox (10 to 20 mg/kg/Day) in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2- Year Duration) |
Completed |
NCT00171301 |
Phase 4 |
Deferasirox |
5 |
A Single-arm Interventional Phase IV, Post-authorisation Study Evaluating the Safety of Pediatric Patients With Transfusional Hemosiderosis Treated With Deferasirox Crushed Film Coated Tablets |
Completed |
NCT03372083 |
Phase 4 |
Deferasirox |
6 |
Erythrocytapheresis Versus Phlebotomy as Maintenance Therapy in Patients With Hereditary Hemochromatosis; a Randomised, Single Blinded Sequential, Cross-over Trial |
Unknown status |
NCT01398644 |
Phase 3 |
|
7 |
A Prospective Randomized Comparative Study of Efficacy and Safety of Combined Deferiprone (DFP) and Deferasirox Versus DFP and Desferrioxamine (DFO) Therapy in Diseases With Severe Iron Overload |
Unknown status |
NCT01511848 |
Phase 2, Phase 3 |
DFP (ferriprox) and deferasirox (ICL 670);DFP, DFO |
8 |
Clinical Management of Hereditary Hemochromatosis: Phlebotomy vs. Erythrocytoapheresis |
Completed |
NCT00440986 |
Phase 2, Phase 3 |
|
9 |
Therapeutic Erythrocytapheresis as Treatment for Hemochromatosis Patients. |
Completed |
NCT00202436 |
Phase 3 |
|
10 |
Randomized Open-label Phase III Study With Deferiprone and/or Desferrioxamine in Iron Overloaded Patients |
Completed |
NCT00350662 |
Phase 3 |
Deferiprone (L1);Desferrioxamine |
11 |
Open Label, Multicenter Study to Evaluate Safety/Tolerability and Efficacy of Deferasirox (ICL670) in Myelodysplastic Syndrome Patients With Chronic Transfusional Hemosiderosis. |
Completed |
NCT00469560 |
Phase 3 |
Deferasirox |
12 |
A Study of Efficacy and Safety of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis |
Completed |
NCT00171171 |
Phase 3 |
deferasirox |
13 |
Stroke With Transfusions Changing to Hydroxyurea |
Terminated |
NCT00122980 |
Phase 3 |
Hydroxyurea |
14 |
Clinical Importance of Treating Iron Overload in Sickle Cell Disease |
Terminated |
NCT00981370 |
Phase 3 |
deferasirox |
15 |
A Phase I/II Open Label, Dose Escalation Trial and a Six Month Extension to Explore the Safety and Efficacy of ICL670 in Patients With Iron Overload Resulting From Hereditary Hemochromatosis. |
Completed |
NCT00395629 |
Phase 1, Phase 2 |
Deferasirox (ICL670) |
16 |
Open-label Study of PTG-300 in Subjects With Hereditary Hemochromatosis |
Completed |
NCT04202965 |
Phase 2 |
PTG-300 |
17 |
A Phase 2, Multi-Center, Randomized, Placebo Controlled, Single-Blind Study With LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis |
Completed |
NCT03395704 |
Phase 2 |
LJPC-401;Placebo |
18 |
Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis |
Completed |
NCT00000595 |
Phase 2 |
deferoxamine |
19 |
Prospective, Comparative (5 Groups), Non-randomized, Multicenter, Physiopathological Study, Evaluating Pharmacokinetic Characteristics of Serum Hepcidin Level in Response to Iron Oral Intake in Order to Evaluate Their Interest to Discriminate Patients With Dysmetabolic Hepatosiderosis or Ferroportin Disease. |
Completed |
NCT01949467 |
Phase 2 |
iron fumarate |
20 |
Retrospective and Prospective Multicenter Study Using Deferiprone (L1) Alone or in Combination With Desferrioxamine for the Treatment of Iron Overload in Transfusion-dependent Patients |
Completed |
NCT00349453 |
Phase 2 |
Deferiprone (L1);Desferrioxamine |
21 |
A Multi-Center, Open-label, Non Comparative, Phase II Trial on Efficacy and Safety of ICL670 Given for 1 Year With Dose Adjustments Based on Serum Ferritin in Patients With Chronic Anemia and Transfusional Hemosiderosis Including an Additional 1 Year Extension. |
Completed |
NCT00631163 |
Phase 2 |
Deferasirox (ICL670) |
22 |
Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Other Patients With Rare Chronic Anemia and Transfusional Iron Overload |
Completed |
NCT00303329 |
Phase 2 |
Deferasirox |
23 |
A Multicenter, Randomized, Open-label Phase II Trial Evaluating Deferasirox Compared With Deferoxamine in Patients With Cardiac Iron Overload Due to Chronic Blood Transfusions |
Completed |
NCT00600938 |
Phase 2 |
Core Study: Deferasirox;Core Study: Deferoxamine;Extension: deferoxamine to deferasirox;Extension: deferasirox to deferoxamine;Deferasirox;Deferoxamine |
24 |
Studies of Phlebotomy Therapy in Hereditary Hemochromatosis |
Recruiting |
NCT00007150 |
Phase 2 |
|
25 |
A Phase II, Multicenter, Open-label, Randomized Two-year Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis. |
Active, not recruiting |
NCT03203850 |
Phase 2 |
Deferasirox FCT |
26 |
Treatment of Refractory Hemochromatosis Rheumatism by Anakinra: a Preliminary Phase II Study |
Terminated |
NCT02263638 |
Phase 2 |
Anakinra |
27 |
Deferasirox Versus Venesection in Patients With Hemochromatosis and for Treatment of Transfusional Siderosis in Myelodysplastic Syndrome: Diagnostics and New Biomarkers. |
Terminated |
NCT01892644 |
Phase 2 |
Deferasirox |
28 |
A Trial of Oral Nifedipine for the Treatment of Iron Overload |
Completed |
NCT00712738 |
Phase 1 |
Nifedipine |
29 |
A Phase Ia/Ib Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BBI-001 in Iron Deficient Volunteers and HH Patients |
Recruiting |
NCT05238207 |
Phase 1 |
BBI-001 |
30 |
Therapeutic Effect of Erythrocyte Apheresis as Compared to Full Blood Phlebotomy in Patients With Hereditary Hemochromatosis |
Unknown status |
NCT00509652 |
|
|
31 |
Proton Pump Inhibitors in the Prevention of Iron Reaccumulation in Patient With Hereditary Hemochromatosis |
Unknown status |
NCT01524757 |
|
Pantoprazole |
32 |
Implications for Quality of Life and Quality of Care in Patients With Hereditary Haemochromatosis |
Unknown status |
NCT01991925 |
|
|
33 |
Sun Yat-sen Memorial Hospital |
Unknown status |
NCT02985346 |
Early Phase 1 |
|
34 |
Study of the Association Between Transferrin Saturation and Asthenia in Hemochromatosis |
Completed |
NCT03356548 |
|
|
35 |
Respiratory Variations in Diameters of the Inferior Vena Cava and the Internal Jugular Vein to Assess Blood Withdrawal in Patients With Genetic Hemochromatosis |
Completed |
NCT03066414 |
|
|
36 |
Clinical Course of Patients With Transfusional Hemochromatosis on Deferoxamine |
Completed |
NCT00001203 |
|
|
37 |
Characterization of Cardiac Function in Subjects With Hereditary Hemochromatosis Who Are New York Heart Association Functional Class I |
Completed |
NCT00068159 |
|
|
38 |
Hemochromatosis and Iron Overload Screening Study (HEIRS) |
Completed |
NCT00005541 |
|
|
39 |
Hemochromatosis--Genetic Prevalence and Penetrance |
Completed |
NCT00006312 |
|
|
40 |
Statistical Basis for Hemochromatosis Screening |
Completed |
NCT00005559 |
|
|
41 |
Testing the Efficacy of a Natural Polyphenol Supplement to Inhibit Dietary Iron Absorption in Subjects With Hereditary Hemochromatosis: a Stable Isotope Study |
Completed |
NCT03990181 |
|
|
42 |
Impact of Bloodletting on Iron Metabolism in Type 1 Hemochromatosis: Pathophysiological and Clinical Implications. Pilot Study. |
Completed |
NCT01810965 |
|
|
43 |
HEPFER-Evaluation of a New Phenotypic Biological Marker in Genetic Type 1 Hemochromatosis |
Completed |
NCT01784939 |
|
|
44 |
Bone Status on Patients With Genetic Hemochromatosis : a 3 Years Descriptive and Evolutionary Study. |
Completed |
NCT01556360 |
|
|
45 |
Estimation of Myocardial Iron Overload by 3 Tesla MRI and Cardiac Functional Consequences in Patients With HFE Hereditary Haemochromatosis. Pilot Study |
Completed |
NCT02099214 |
|
|
46 |
Study of the Cellular Diffusion of Tacrolimus Across the Membrane of Mononuclear Cells |
Completed |
NCT03654794 |
|
|
47 |
Iron Overload in African Americans |
Completed |
NCT00001455 |
|
|
48 |
Research Network for Neonatal Diseases Induced by Tissular Fetomaternal Alloimmunization |
Completed |
NCT00199628 |
|
|
49 |
Haemochromatosis and Periodontitis |
Completed |
NCT04006249 |
|
|
50 |
Evaluation of a New MR Pulse Sequence to Quantify Liver Iron Concentration |
Completed |
NCT00587535 |
|
|
Inferred drug relations via
UMLS
71
/
NDF-RT
50
:
Cochrane evidence based reviews: hemochromatosis
|